A Reliable Nomogram is Identified to Predict the Probabilities of Having Indications for Adjuvant Prostatic Radiation Therapy
M. W. Ma,X. S. Gao,M. Xie,Z. G. Zhou,B. Zhao,D. Wang
DOI: https://doi.org/10.1016/j.ijrobp.2016.06.1252
2016-01-01
Abstract:Currently there is no reliable nomogram to predict the probabilities of having indications for adjuvant prostate radiation therapy for patients with clinically localized prostate cancer who plans radical prostatectomy (RP). The purpose of this study is to examine our cohort of RP patients and to develop the above nomogram through the correlation of pretreatment PSA, clinical T stage and biopsy Gleason Score with adverse features such as extraprostatic extension, positive margin(s), and Gleason Score 8-10 that are commonly indicated for adjuvant radiation therapy. We analyzed 1440 RP patients between August, 2000 and August, 2015 at our hospital. Patients who had a history of neoadjuvant hormonal therapy, or transurethral resection of the prostate (TURP) were excluded from this analysis. A total of 627 patients were eligible for analysis. Average age was 66 years. All patients had a preoperative PSA level, biopsy Gleason Score, pelvic MRI and clinical T stage (TNM 2009 classification). Preoperative PSA level clinical T stage (T2a/b, T2c, T3a, T3b), and biopsy Gleason score (5 to 6, 3+4 = 7, 4 + 3 = 7, 8 to 10) were recorded as preoperative predictors. These predictors were used in multivariable logistic regression analysis based nomograms to estimate the probabilities of extraprostatic extension, positive margin(s), Gleason Score 8-10 after RP, respectively. The predictive accuracy and discriminative ability of the nomogram were determined by concordance index (C-index) and calibration curve. Analyses were performed with open-source statistical software (version 3.2.1). Preoperatively, 41% of patients had a PSA level between 10 and 20 ng/mL, 80% had T2, and 50% had biopsy Gleason score 7; postoperatively, 47% had extraprostatic extension disease, 36% had positive margin, and 22% had Gleason Score 8-10. Nomograms were developed for the predicted probabilities of having the indications of adjuvant radiation therapy (pathologically extraprostatic extension disease or positive margin(s), or Gleason Score 8-10, respectively). The calibration curve for probabilities showed good agreement between prediction by nomogram and actual observation. The C-index of the nomograms for predicting for extraprostatic extension disease, or positive margin(s), or Gleason Score 8-10 were 0.707, 0.659, 0.897, respectively. The risk of having one of the indications of adjuvant radiation therapy increased with increases in predictors except for clinical T stage for predicting Gleason Score 8-10 (P = 0.25). Using clinic-pathological information, we produced nomograms which may accurately predict the probabilities of having indications for adjuvant radiation therapy after RP. This nomogram may help individualize initial treatment options.